To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets Combined With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects, aged 18-55 (including boundary);
- Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and <90 kg , female body weight ≥45kg and <90kg;
- Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters,etc.
- Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.
Exclusion Criteria:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin > 1.2 fold ULN during screening/baseline.
- Serum creatinine> ULN during screening/baseline.
- Positive faecal occult blood
- Abnormal coagulation function.
- A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.
- Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.
- Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.
- Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.
- 3 months prior to screening involved in any drug or medical device clinical studies. .
- Female subjects who did not receive contraception at least 30 days before administration and etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: group A: Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)
|
groupA: Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ;
groupB: Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
|
|
Experimental: group B :Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)
|
groupA: Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ;
groupB: Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
|
|
Experimental: group C: Aspirin + Ticagrelor + placebo or SHR2285
|
groupC: Aspirin + ticagrelor + placebo or SHR2285
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects with adverse events and severity of adverse events.
Time Frame: from the first dose to 48hours after the last dose
|
from the first dose to 48hours after the last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: from Day1 to Day8 after the first dose
|
Maximum observed serum concentration (Cmax) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
Tmax
Time Frame: from Day1 to Day8 after the first dose
|
Time to maximum observed serum concentration (Tmax) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
T1/2
Time Frame: from Day1 to Day8 after the first dose
|
Time to elimination half-life (T1/2) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
AUC0-last
Time Frame: from Day1 to Day8 after the first dose
|
Area under the plasma concentration versus time curve (AUC0-last) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
Cmax,ss
Time Frame: from Day1 to Day8 after the first dose
|
Steady-state peak concentration (Cmax,ss) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
Ctrough,ss
Time Frame: from Day1 to Day8 after the first dose
|
Steady state valley concentration (Ctrough,ss) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.
|
from Day1 to Day8 after the first dose
|
|
FXI activity
Time Frame: from Day1 to Day8 after the first dose
|
Clotting factor XI (FXI) activity
|
from Day1 to Day8 after the first dose
|
|
APTT
Time Frame: from Day1 to Day8 after the first dose
|
Change of activated partial thromboplastin time (APTT) from baseline
|
from Day1 to Day8 after the first dose
|
|
PT
Time Frame: from Day1 to Day8 after the first dose
|
Change of prothrombin time (PT) from baseline
|
from Day1 to Day8 after the first dose
|
|
INR
Time Frame: from Day1 to Day8 after the first dose
|
Change of international normalization ratio (INR) from baseline
|
from Day1 to Day8 after the first dose
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thrombosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
Other Study ID Numbers
- SHR2285-106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.